Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive status confers therapeutic sensitivity to Anastrozole in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer.
This statement is based on a regulatory approval from the Health Products Regulatory Authority:
Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women.